MicrodosingPsilocybinLSD

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

This online survey (n=6,193; 2,488 microdosers) examines differences between exclusive microdosers and those who use both micro and macrodoses of psychedelics. The study finds exclusive microdosers were typically older, more likely to be female and non-Caucasian, with psilocybin (74.5%) and LSD (34.4%) being the most commonly used substances, primarily for general wellbeing (73.0%).

Authors

  • Philippe Lucas
  • Muhammad Ishrat Husain
  • Rotem Petranker

Published

Journal of Psychoactive Drugs
individual Study

Abstract

Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193 psychedelic consumers of which 2488 were microdosers of up to 11 different classical and atypical psychedelics. In comparison to respondents that use both microdoses and macrodoses, exclusive microdosers were older in age (46.4 vs. 42.0 years), had a larger proportion of females (68.4% vs. 44.7%), were non-Caucasian (25.4% vs. 14.7%), urban residents (43.9% vs. 38.5%), and had a lower average lifetime use of non-psychedelic substances (3.8 vs. 4.7 substances). Most consumers (52.5%) microdosed psychedelics multiple times a month, commonly using psilocybin(74.5%), LSD (34.4%), and ketamine (15.8%), with most users (64.6%) not testing their substances. The most common reason for microdosing was improving general wellbeing (73.0%), and psychedelics were used for treating several physical and mental health conditions. Additional analyses examined spending habits of consumers. This study adds to the growing literature on the naturalistic use of psychedelic microdosers.

Available with Blossom Pro

Research Summary of 'Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use'

Introduction

Syed and colleagues situate microdosing within the broader recent revival of psychedelic research, noting that clinical work has chiefly focused on moderate-to-large doses that produce pronounced subjective effects. They point out a parallel, growing public practice of taking sub-hallucinogenic ‘‘microdoses’’ with reported cognitive and psychological benefits, but emphasise that rigorous evidence is limited: randomized controlled trials and self-blinded studies have produced mixed or null findings, while much of the existing literature remains cross‑sectional and survey‑based. This study aims to fill a specific gap by distinguishing people who exclusively microdose from those who both microdose and take larger, hallucinogenic doses. The investigators set out to (1) validate prior findings about microdosing frequency and substance-testing behaviour in a large global sample, and (2) characterise demographic differences, practices, motivations, and perceptions between exclusive microdosers and those who combine micro- and macrodoses. Four pre-registered hypotheses addressed typical frequency, reasons for use, rates of substance testing, and relative lifetime use of non-psychedelic substances between the two groups.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (24)

Papers cited by this study that are also in Blossom

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)

142 cited
21 cited
Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research

Bornemann, J., Spriggs, M. J., Carhart-Harris, R. L. et al. · Frontiers in Psychiatry (2021)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

90 cited
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M. et al. · Journal of Psychopharmacology (2021)

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Motives and side-effects of microdosing with psychedelics among users

Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · International Journal of Neuropsychopharmacology (2019)

Show all 24 references
Powerful substances in tiny amounts An interview study of psychedelic microdosing

Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)

121 cited
The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

Kuypers, K. P. C., Erritzoe, D., Knudsen, G. M. et al. · Journal of Psychopharmacology (2019)

Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited
Microdosing psilocybin for chronic pain: a case series

Lyes, M., Yang, K. H., Castellanos, J. P. et al. · PAIN (2022)

A systematic study of microdosing psychedelics

Polito, V., Stevenson, R. J. · PLOS ONE (2019)

197 cited
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting

Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)

55 cited
Body mass index (BMI) does not predict responses to psilocybin

Giribaldi, B., Lyons, T., Rosas, F. E. et al. · Journal of Psychopharmacology (2022)

15 cited
Self-blinding citizen science to explore psychedelic microdosing

Szigeti, B., Kartner, L., Blemings, A. et al. · eLife (2021)

128 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.